En-tête de navigationNavigation principaleSuiviFiche


Unité de recherche
PCRD EU
Numéro de projet
00.0234
Titre du projet
CONTEXTH: New systems of controlled gene expression for improved delivery of therapeutic substances.
Titre du projet anglais
CONTEXTH: New systems of controlled gene expression for improved delivery of therapeutic substances.

Textes relatifs à ce projet

 AllemandFrançaisItalienAnglais
Mots-clé
-
-
-
Anzeigen
Autre Numéro de projet
-
-
-
Anzeigen
Programme de recherche
-
-
-
Anzeigen
Description succincte
-
-
-
Anzeigen
Partenaires et organisations internationales
-
-
-
Anzeigen
Résumé des résultats (Abstract)
-
-
-
Anzeigen
Références bases de données
-
-
-
Anzeigen

Textes saisis


CatégorieTexte
Mots-clé
(Anglais)
Heterologous gene regulation; tet system; pip system; streptogramin; tetracycline; dual regulation;
Biotechnology; Environmental Protection; Innovation; Technology Transfer; Life Sciences; Medicine; Health; Waste Management
Autre Numéro de projet
(Anglais)
EU project number: QLK3-2000-00721
Programme de recherche
(Anglais)
EU-programme: 5. Frame Research Programme - 1.1.3 The 'cell factory'
Description succincte
(Anglais)
See abstract
Partenaires et organisations internationales
(Anglais)
Coordinator: Institut National de la Santé (INSERM) (F)
Résumé des résultats (Abstract)
(Anglais)
This proposal wishes to contribute to the development of new treatments against high frequency diseases that are cancers, retinopathies and arteriosclerosis, touching up to 42% of the population.
The proposed approach is to create new gene-transfer systems based on programs of coupled transcriptional and post-transcriptional regulations of gene expression, for an efficient and controlled delivery of active therapeutic agents. Regulatory tools emerging from fundamental research results will allow the creation of new vectors and genetically modified cells efficiently expressing combinations of antiangiogenic agents or growth factors and cytokines.
Antiangiogenesis can target up to 100% of solid tumours and most retinopathies. Angiogenic and anti-inflammatory agents target atheroma plaque, to prevent myocardial infarction. The vectors and cell lines delivering therapeutic substances, tested on animals models, will be commercialised to big industrial companies in Europe that think launching clinical assays and exploit them in a large scale. This program is expected to create a large added value for European community.
Références bases de données
(Anglais)
Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. +41 31 322 74 82
Swiss Project-Number: 00.0234